Ryvu Therapeutics S.A.

DB:9Y4 Stock Report

Market Cap: €142.6m

Ryvu Therapeutics Valuation

Is 9Y4 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 9Y4 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 9Y4's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 9Y4's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 9Y4?

Key metric: As 9Y4 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 9Y4. This is calculated by dividing 9Y4's market cap by their current revenue.
What is 9Y4's PS Ratio?
PS Ratio6.6x
Saleszł91.18m
Market Capzł601.12m

Price to Sales Ratio vs Peers

How does 9Y4's PS Ratio compare to its peers?

The above table shows the PS ratio for 9Y4 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.2x
EVT Evotec
2x12.2%€1.5b
GXI Gerresheimer
1.2x9.5%€2.3b
1SXP SCHOTT Pharma KGaA
3.7x9.3%€3.6b
991 Vitruvia Medical
1.8xn/a€3.2m
9Y4 Ryvu Therapeutics
6.6x19.3%€601.1m

Price-To-Sales vs Peers: 9Y4 is expensive based on its Price-To-Sales Ratio (6.6x) compared to the peer average (2.2x).

Price to Sales Ratio vs Industry

How does 9Y4's PS Ratio compare vs other companies in the European Life Sciences Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
9Y4 6.6xIndustry Avg. 4.2xNo. of Companies6PS03.26.49.612.816+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 9Y4 is expensive based on its Price-To-Sales Ratio (6.6x) compared to the European Life Sciences industry average (4.2x).

Price to Sales Ratio vs Fair Ratio

What is 9Y4's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

9Y4 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.6x
Fair PS Ratio2.5x

Price-To-Sales vs Fair Ratio: 9Y4 is expensive based on its Price-To-Sales Ratio (6.6x) compared to the estimated Fair Price-To-Sales Ratio (2.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 9Y4 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€6.43
€15.58
+142.4%
22.8%€18.94€9.66n/a4
Jan ’26€8.81
€15.41
+74.9%
22.8%€18.73€9.55n/a4
Dec ’25€10.24
€19.24
+87.9%
18.4%€25.17€15.95n/a4
Nov ’25€10.38
€18.44
+77.6%
16.4%€23.26€15.70n/a4
Oct ’25€11.88
€18.44
+55.2%
16.4%€23.26€15.70n/a4
Sep ’25€12.18
€17.81
+46.2%
17.5%€22.68€14.62n/a4
Aug ’25€11.60
€17.81
+53.5%
17.5%€22.68€14.62n/a4
Jul ’25€11.34
€17.81
+57.0%
17.5%€22.68€14.62n/a4
Jun ’25€12.34
€16.56
+34.2%
9.5%€18.70€14.96n/a3
May ’25€11.04
€16.96
+53.7%
9.7%€18.56€14.85n/a4
Apr ’25€12.54
€16.78
+33.8%
8.5%€18.68€14.94n/a4
Mar ’25€13.42
€16.94
+26.2%
9.7%€18.53€14.82n/a4
Feb ’25€12.86
€16.44
+27.8%
12.1%€18.41€14.20€6.434
Jan ’25€13.48
€16.44
+22.0%
12.1%€18.41€14.20€8.814
Dec ’24€12.88
€16.44
+27.6%
12.1%€18.41€14.20€10.244
Nov ’24€13.56
€15.80
+16.5%
10.5%€17.95€13.84€10.384
Oct ’24€13.12
€15.62
+19.1%
11.1%€17.44€13.28€11.883
Sep ’24€12.76
€16.45
+28.9%
11.1%€18.36€13.98€12.183
Aug ’24€12.90
€16.45
+27.5%
11.1%€18.36€13.98€11.603
Jul ’24€12.86
€15.71
+22.2%
10.7%€17.40€13.42€11.343
Jun ’24€11.86
€15.71
+32.5%
10.7%€17.40€13.42€12.343
May ’24€11.94
€15.71
+31.6%
10.7%€17.40€13.42€11.043
Apr ’24€12.06
€15.45
+28.1%
10.7%€17.11€13.20€12.543
Mar ’24€12.56
€13.17
+4.9%
21.5%€16.75€9.84€13.423
Feb ’24€11.00
€11.76
+6.9%
15.6%€13.60€9.92€12.862
Analyst Price Target
Consensus Narrative from 4 Analysts
€16.28
Fair Value
60.5% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 22:47
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ryvu Therapeutics S.A. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamil KliszczBiuro maklerskie mBanku
Beata Szparaga-WasniewskaBiuro maklerskie mBanku
Jonas PeciulisEdison Investment Research